| CLPBY Stock | | | USD 12.51 0.15 1.21% |
EVP
Mr. Allan Rasmussen was Executive Vice President, Global Operations and Member of the Executive Management at Coloplast AS since July 1, 2014. He no longer serves as Senior Vice President, Global Operations of the Company, effective as of July 1, 2014. He was employed at the Company since 1992. He graduated in BPSE from IMD in 2007. He also holds an Executive MBA degree from Scandinavian International Management Institute from 2001 and BS degree in Mechanical Engineering from Danmarks Tekniske Universitet from 1992. since 2014.
| Age | 56 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Phone | 45 49 11 11 11 |
| Web | https://www.coloplast.com |
Coloplast Management Efficiency
The company has return on total asset
(ROA) of
0.1714 % which means that it generated a profit of $0.1714 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.7507 %, meaning that it generated $0.7507 on every $100 dollars invested by stockholders. Coloplast's management efficiency ratios could be used to measure how well Coloplast manages its routine affairs as well as how well it operates its assets and liabilities.
Coloplast A has accumulated 16.36
B in total debt with debt to equity ratio
(D/E) of 2.83, implying the company greatly
relies on financing operations through barrowing. Coloplast A has a current ratio of 0.99, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Coloplast until it has trouble settling it off, either with new capital or with free cash flow. So, Coloplast's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Coloplast A sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Coloplast to invest in growth at high rates of return. When we think about Coloplast's use of debt, we should always consider it together with cash and equity.
Coloplast AS engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. Coloplast AS was founded in 1954 and is headquartered in Humlebk, Denmark. Coloplast is traded on OTC Exchange in the United States. Coloplast A [CLPBY] is a
Pink Sheet which is traded between brokers over the counter.
Management Performance
Coloplast A Leadership Team
Elected by the shareholders, the Coloplast's board of directors comprises two types of representatives: Coloplast inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Coloplast. The board's role is to monitor Coloplast's management team and ensure that shareholders' interests are well served. Coloplast's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Coloplast's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ellen Bjurgert, VP Relations | |
| Allan Rasmussen, Executive VP of Global Operations | |
| Alain Morvan, Senior Vice President Sales Europe | |
| Thomas Barfod, Director, Employee Representative | |
| Nicolai Andersen, Senior Vice President Wound Care | |
| Anders LonningSkovgaard, CFO, Executive Vice President Member of the Executive Management | |
| Kristian Villumsen, Executive VP of Chronic Care | |
| Paul Marcun, Senior Vice President Emerging Markets | |
| Dorthe Ronnau, VP Culture | |
| Dennis Kaysen, Director Communications | |
Coloplast Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Coloplast a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Coloplast Pink Sheet Analysis
When running Coloplast's price analysis, check to
measure Coloplast's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coloplast is operating at the current time. Most of Coloplast's value examination focuses on studying past and present price action to
predict the probability of Coloplast's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coloplast's price. Additionally, you may evaluate how the addition of Coloplast to your portfolios can decrease your overall portfolio volatility.